116 related articles for article (PubMed ID: 15637138)
1. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.
Asnafi V; Buzyn A; Thomas X; Huguet F; Vey N; Boiron JM; Reman O; Cayuela JM; Lheritier V; Vernant JP; Fiere D; Macintyre E; Dombret H
Blood; 2005 Apr; 105(8):3072-8. PubMed ID: 15637138
[TBL] [Abstract][Full Text] [Related]
2. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.
Dombret H; Gabert J; Boiron JM; Rigal-Huguet F; Blaise D; Thomas X; Delannoy A; Buzyn A; Bilhou-Nabera C; Cayuela JM; Fenaux P; Bourhis JH; Fegueux N; Charrin C; Boucheix C; Lhéritier V; Espérou H; MacIntyre E; Vernant JP; Fière D;
Blood; 2002 Oct; 100(7):2357-66. PubMed ID: 12239143
[TBL] [Abstract][Full Text] [Related]
3. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage.
Asnafi V; Radford-Weiss I; Dastugue N; Bayle C; Leboeuf D; Charrin C; Garand R; Lafage-Pochitaloff M; Delabesse E; Buzyn A; Troussard X; Macintyre E
Blood; 2003 Aug; 102(3):1000-6. PubMed ID: 12676784
[TBL] [Abstract][Full Text] [Related]
4. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy.
Asnafi V; Beldjord K; Libura M; Villarese P; Millien C; Ballerini P; Kuhlein E; Lafage-Pochitaloff M; Delabesse E; Bernard O; Macintyre E
Blood; 2004 Dec; 104(13):4173-80. PubMed ID: 15054041
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
Raanani P; Shpilberg O; Gillis S; Avigdor A; Hardan I; Berkowicz M; Sofer O; Lossos I; Chetrit A; Ben-Yehuda D; Ben-Bassat I
Leuk Res; 1999 Aug; 23(8):695-700. PubMed ID: 10456666
[TBL] [Abstract][Full Text] [Related]
7. Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia.
Reman O; Buzyn A; Lhéritier V; Huguet F; Kuentz M; Stamatoullas A; Delannoy A; Fegueux N; Micléa JM; Boiron JM; Vernant JP; Gardin C; Hacini M; Georges M; Fière D; Thomas X;
Hematol J; 2004; 5(2):123-9. PubMed ID: 15048062
[TBL] [Abstract][Full Text] [Related]
8. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
9. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Dekker AW; van't Veer MB; Sizoo W; Haak HL; van der Lelie J; Ossenkoppele G; Huijgens PC; Schouten HC; Sonneveld P; Willemze R; Verdonck LF; van Putten WL; Löwenberg B
J Clin Oncol; 1997 Feb; 15(2):476-82. PubMed ID: 9053468
[TBL] [Abstract][Full Text] [Related]
10. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols.
van Grotel M; Meijerink JP; Beverloo HB; Langerak AW; Buys-Gladdines JG; Schneider P; Poulsen TS; den Boer ML; Horstmann M; Kamps WA; Veerman AJ; van Wering ER; van Noesel MM; Pieters R
Haematologica; 2006 Sep; 91(9):1212-21. PubMed ID: 16956820
[TBL] [Abstract][Full Text] [Related]
11. T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome.
Baleydier F; Decouvelaere AV; Bergeron J; Gaulard P; Canioni D; Bertrand Y; Lepretre S; Petit B; Dombret H; Beldjord K; Molina T; Asnafi V; Macintyre E
Clin Cancer Res; 2008 Feb; 14(3):692-700. PubMed ID: 18245528
[TBL] [Abstract][Full Text] [Related]
12. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
de Labarthe A; Rousselot P; Huguet-Rigal F; Delabesse E; Witz F; Maury S; Réa D; Cayuela JM; Vekemans MC; Reman O; Buzyn A; Pigneux A; Escoffre M; Chalandon Y; MacIntyre E; Lhéritier V; Vernant JP; Thomas X; Ifrah N; Dombret H;
Blood; 2007 Feb; 109(4):1408-13. PubMed ID: 17062730
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
Liedtke M; Dunn T; Dinner S; Coutré SE; Berube C; Gotlib J; Patel S; Medeiros B
Leuk Res; 2014 Dec; 38(12):1441-5. PubMed ID: 25449689
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Milpied N; Gisselbrecht C; Harousseau JL; Sebban C; Witz F; Troussard X; Gratecos N; Michallet M; LeBlond V; Auzanneau G
Cancer; 1990 Aug; 66(4):627-31. PubMed ID: 2386891
[TBL] [Abstract][Full Text] [Related]
15. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
16. Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: response to treatment and factors influencing outcome.
Sierra J; Grañena A; Bosch F; Carreras E; Martí JM; Urbano-Ispizua A; Rovira M; Rozman C
Hematol Oncol; 1992; 10(6):301-9. PubMed ID: 1296931
[TBL] [Abstract][Full Text] [Related]
17. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
[TBL] [Abstract][Full Text] [Related]
18. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.
Arlin ZA; Feldman EJ; Finger LR; Ahmed T; Mittelman A; Cook P; Puccio C; Baskind P; Arnold P; Razis ED
Leukemia; 1991 Aug; 5(8):712-4. PubMed ID: 1886423
[TBL] [Abstract][Full Text] [Related]
19. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Kern W; Schleyer E; Braess J; Wittmer E; Ohnesorge J; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Ann Hematol; 2001 Jun; 80(6):334-9. PubMed ID: 11475146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
